Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
Status:
Completed
Trial end date:
2018-01-17
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth and by blocking blood flow to the tumor. Giving temozolomide together with
sunitinib malate may kill more tumor cells.
Phase II was never conducted due to toxicity in phase I.
PURPOSE: This phase I/II trial is studying the side effects and best dose of sunitinib malate
when given together with temozolomide and to see how well they work in treating patients with
stage III or stage IV malignant melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) Pfizer Schering-Plough